Cerus (CERS) Institutional Ownership : 57.15% (As of Apr. 25, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Cerus Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cerus's institutional ownership is 57.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cerus's Insider Ownership is 5.52%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cerus's Float Percentage Of Total Shares Outstanding is 97.04%.

Cerus Institutional Ownership Historical Data

The historical data trend for Cerus's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Institutional Ownership Chart

Cerus Historical Data

The historical data trend for Cerus can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	63.34	63.08	62.97	59.87	57.09	56.71	57.31	56.89	56.76	57.15

Cerus Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Cerus (CERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CU2:Germany

Address

1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520

Website

http://www.cerus.com

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Executives

Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena	director	C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Gail Schulze	director	3451 WELLS ROAD, MALVERN PA 19355
Laurence M Corash	director	C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
William Mariner Greenman	officer: President, Cerus Europe	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard	officer: Chief Legal Officer	C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green	officer: Chief Accounting Officer	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin	officer: Chief Medical Officer	15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman	officer: Chief Commercial Officer	3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Hua Shan	director	C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Carol Moore	officer: SR. V.P. Regulatory, Clinical	C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Timothy B Anderson	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Timothy L. Moore	director	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Frank Witney	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451